• Citer

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).

par Shorr, Andrew F;Janes, Jonathan;Artigas, Antonio;Tenhunen, Jyrki;Wyncoll, Duncan L A;Mercier, Emmanuelle;François, Bruno;Vincent, Jean Louis ;Vangerow, Burkhard;Heiselman, Darell;Leishman, Amy G;Zhu, Yajun E;Reinhart, Konrad;RESPOND investigators,
Référence Critical care, 14, 6, page (R229)
Publication Publié, 2010

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Serial alterations in protein C levels appear to correlate with disease severity in patients with severe sepsis, and it may be possible to tailor severe sepsis therapy with the use of this biomarker. The purpose of this study was to evaluate the dose and duration of drotrecogin alfa (activated) treatment using serial measurements of protein C compared to standard therapy in patients with severe sepsis.